Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus Sepsis.

Abzug MJ, Michaels MG, Wald E, Jacobs RF, Romero JR, Sánchez PJ, Wilson G, Krogstad P, Storch GA, Lawrence R, Shelton M, Palmer A, Robinson J, Dennehy P, Sood SK, Cloud G, Jester P, Acosta EP, Whitley R, Kimberlin D; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.

J Pediatric Infect Dis Soc. 2016 Mar;5(1):53-62. doi: 10.1093/jpids/piv015. Epub 2015 Apr 16.

2.

An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer.

Waller CF, Vynnychenko I, Bondarenko I, Shparyk Y, Hodge JP, Freeman A, Huber B, Lieberman R, Shelton MJ, Dave H.

Clin Lung Cancer. 2015 Mar;16(2):92-9. doi: 10.1016/j.cllc.2014.10.001. Epub 2014 Oct 15.

PMID:
25458558
3.

Oral acyclovir suppression and neurodevelopment after neonatal herpes.

Kimberlin DW, Whitley RJ, Wan W, Powell DA, Storch G, Ahmed A, Palmer A, Sánchez PJ, Jacobs RF, Bradley JS, Robinson JL, Shelton M, Dennehy PH, Leach C, Rathore M, Abughali N, Wright P, Frenkel LM, Brady RC, Van Dyke R, Weiner LB, Guzman-Cottrill J, McCarthy CA, Griffin J, Jester P, Parker M, Lakeman FD, Kuo H, Lee CH, Cloud GA; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.

N Engl J Med. 2011 Oct 6;365(14):1284-92. doi: 10.1056/NEJMoa1003509.

4.

Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects.

Shelton MJ, Lovern M, Ng-Cashin J, Jones L, Gould E, Gauvin J, Rodvold KA.

Antimicrob Agents Chemother. 2011 Nov;55(11):5178-84. doi: 10.1128/AAC.00703-11. Epub 2011 Sep 6.

5.

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.

Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, Shelton M, Kerkar N, Galoppo M, Pedreira A, Rodriguez-Baez N, Ciocca M, Lachaux A, Lacaille F, Lang T, Kullmer U, Huber WD, Gonzalez T, Pollack H, Alonso E, Broue P, Ramakrishna J, Neigut D, Valle-Segarra AD, Hunter B, Goodman Z, Xu CR, Zheng H, Noviello S, Sniukiene V, Brass C, Albrecht JK.

J Hepatol. 2010 Apr;52(4):501-7. doi: 10.1016/j.jhep.2010.01.016. Epub 2010 Feb 4.

PMID:
20189674
6.

Safety of oseltamivir compared with the adamantanes in children less than 12 months of age.

Kimberlin DW, Shalabi M, Abzug MJ, Lang D, Jacobs RF, Storch G, Bradley JS, Wade KC, Ramilo O, Romero JR, Shelton M, Leach C, Guzman-Cottrill J, Robinson J, Abughali N, Englund J, Griffin J, Jester P, Cloud GA, Whitley RJ; NIAID Collaborative Antiviral Study Group.

Pediatr Infect Dis J. 2010 Mar;29(3):195-8. doi: 10.1097/INF.0b013e3181bbf26b.

7.

Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system.

Oliver SE, Cloud GA, Sánchez PJ, Demmler GJ, Dankner W, Shelton M, Jacobs RF, Vaudry W, Pass RF, Soong SJ, Whitley RJ, Kimberlin DW; National Institute of Allergy, Infectious Diseases Collaborative Antiviral Study Group.

J Clin Virol. 2009 Dec;46 Suppl 4:S22-6. doi: 10.1016/j.jcv.2009.08.012. Epub 2009 Sep 18.

8.

Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects.

Ford SL, Chen YC, Lou Y, Borland J, Min SS, Yuen GJ, Shelton MJ.

Antimicrob Agents Chemother. 2008 Feb;52(2):534-8. Epub 2007 Dec 3.

9.

Multiple-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in HIV-Infected Patients.

Morse GD, Cohn SE, Shelton MJ, Greisberger C, Cox SR, Della-Coletta AA, Freimuth WW, Reichman RC.

Clin Drug Investig. 2003;23(5):323-8.

PMID:
17535044
10.

Effect of Food on the Steady-State Pharmacokinetics of Delavirdine in Patients with HIV Infection.

Morse GD, Fischl MA, Shelton MJ, Cox SR, Thompson L, Della-Coletta AA, Freimuth WW.

Clin Drug Investig. 2003;23(4):255-61.

PMID:
17535038
11.

Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.

Wire MB, Ballow CH, Borland J, Shelton MJ, Lou Y, Yuen G, Lin J, Lewis EW.

Antimicrob Agents Chemother. 2007 Aug;51(8):2982-4. Epub 2007 May 21.

12.

Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.

Ruane PJ, Luber AD, Wire MB, Lou Y, Shelton MJ, Lancaster CT, Pappa KA; COL10053 Study Team.

Antimicrob Agents Chemother. 2007 Feb;51(2):560-5. Epub 2006 Nov 6.

13.

Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.

DeJesus E, Piliero PJ, Summers K, Wire MB, Stein DS, Masterman A, Lou Y, Min SS, Shelton MJ.

Antimicrob Agents Chemother. 2006 Sep;50(9):3157-9.

14.

Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics.

Shelton MJ, Ford SL, Borland J, Lou Y, Wire MB, Min SS, Xue ZG, Yuen G.

J Acquir Immune Defic Syndr. 2006 May;42(1):61-7.

PMID:
16639341
15.

Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.

Wire MB, Baker KL, Jones LS, Shelton MJ, Lou Y, Thomas GJ, Berrey MM.

Antimicrob Agents Chemother. 2006 Apr;50(4):1578-80.

16.

Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.

Shelton MJ, Wire MB, Lou Y, Adamkiewicz B, Min SS.

Antimicrob Agents Chemother. 2006 Mar;50(3):928-34.

17.

Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.

Wire MB, Shelton MJ, Studenberg S.

Clin Pharmacokinet. 2006;45(2):137-68. Review.

PMID:
16485915
18.

Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.

González-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, Shelton M, Mieli-Vergani G, Lurie Y, Martin S, Lang T, Baczkowski A, Geffner M, Gupta S, Laughlin M; International Pediatric Hepatitis C Therapy Group.

Hepatology. 2005 Nov;42(5):1010-8.

PMID:
16250032
19.

Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.

Smith PF, Dicenzo R, Forrest A, Shelton M, Friedland G, Para M, Pollard R, Fischl M, DiFrancesco R, Morse GD.

Clin Pharmacokinet. 2005;44(1):99-109.

PMID:
15634033
20.

The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone.

Shelton MJ, Cloen D, DiFrancesco R, Berenson CS, Esch A, de Caprariis PJ, Palic B, Schur JL, Buggé CJ, Ljungqvist A, Espinosa O, Hewitt RG.

J Clin Pharmacol. 2004 Mar;44(3):293-304.

PMID:
14973306

Supplemental Content

Loading ...
Support Center